Cristiana Sieiro Santos
Cristiana is a rheumatology consultant at Complejo Asistencial Universitario de León (Spain) focusing on SLE and SSc, currently responsible for a nailfoldvideocapillaroscopy and ILD-associated CTD outpatient clinic. She is a PhD student of the Doctoral Program of Biomedical Sciences focusing on the immuneresponses to conventional vaccines in patients with immune-mediated diseases.
| Oral 0208 | Thursday 13.06.24 15:45 What you wanted to know about mithocondria Author: Lindblom, J (Sweden) Title: Lymphocyte, NK cell and Mitochondrial gene dysregulation patterns separate patients with neuropsychiatric systemic lupus erythematosus into distinct subgroups with differential anticipated response to targeted therapies  B cell, T cell, cytotoxic/NK cell, and mitochondrial gene dysregulation patterns separated active CNS lupus patients into two distinct subgroups with differential anticipated response to type I interferon and calcineurin inhibition. |
| Oral 0299 | Friday 14.06.2024 10:30 Clinical Abstract Sessions: Evaluating the complexities of Antiphospholipid Syndrome Author: Gaspar, P (Portugal) Title: Adjusted global antiphospholipid syndrome score (AGAPSS) at diagnosis and persistent antiphospholipid antibodies are stronger predictors of recurrent thrombosis in primary antiphospholipid syndrome An aGAPSS ≥7 at diagnosis accurately predicted thrombotic recurrences, with better diagnostic accuracy than at follow-up. Persistent antiphospholipid antibodies (aPL) may serve as a more reliable predictor of recurrent thrombosis in pAPS |
| Oral 0160| Thursday 13.06.2024 10:30 Clinical Abstract Sessions: Systemic lupus and MCTD – Diagnosing and managing complex diseases Author: Altabás Gonzále, I (Spain) Title: Proposal and validation of new activity states definitions according severity in Systemic Lupus Erythematosus on the basis of RELESSER-PROS register database Patients who were in a state of moderate or severe activity at least one time had worse outcomes at the end of follow-up in terms of damage accrual, hospital admissions, number of flares and deterioration in HRQoL. |
| Oral 0043 | Wednesday 12.06.2024 16:30 Clinical Abstract Sessions: Novel treatment avenues in SLE Author: Rodziewicz, M (UK) Title: The effectiveness of rituximab in the real-world treatment of neuropsychiatric SLE: results from the British Iles Lupus Assessment Group Biologics Register (BILAG-BR) This is the largest reported cohort of rituximab-treated NPSLE-treated patients. Rituximab appears effective in the treatment of moderate-severe NPSLE and is associated with lower steroid dose at 6 months |
| Poster 1393 | Saturday 15.06.2024 10:15 Poster View VII Author: Scherlinger, M (France) Title: Lupus pregnancies are characterized by a distinct inflammatory transcriptomic signature partly driven by specific miRNA SLE pregnancies have a distinct monocyte transcriptomic signature which differs from healthy and RA pregnancies, that accompany increased risk of disease flares and adverse pregnancy events. |
| Poster 0537 | Wednesday 12.06.24 15:30 Poster View I Author: Dyball, S (UK) Title: Global perspectives on glucocorticoid management in systemic lupus erythematosus: results from the LUPHPOS survey Physician location influences GC prescribing practices and safety considerations, impacting dosing selection, withdrawal, and tapering strategies. These geographical disparities underscore the need for a consensus on evidence-based care, and global implementation and dissemination strategies. |
| Poster 0046 | Wednesday 12.06.2024 15:30 Clinical Poster Tours: Systemic lupus – Of old and new therapies Author: Cortés-Hernández, J (Spain) Title: Preliminary results of an open-label, multicentre, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 (rapcabtagene autoleucel), a rapidly manufactured car t-cell therapy targeting cd19 on b cells, for severe refractory systemic lupus erythematosus Preliminary data from this clinical trial suggest favourable safety, CAR T-cell expansion, B-cell depletion and initial efficacy of YTB323 in srSLE |